综述

慢性咳嗽:现状与展望

  • 刘路 ,
  • 祝筱姬 ,
  • 钟玉绪
展开
  • 1.同济大学附属东方医院胶州医院呼吸内科 (山东 青岛 266300 )
    2.中国人民解放军军事科学院军事医学研究院毒物药物研究所 (北京 100850 )

收稿日期: 2024-03-10

  网络出版日期: 2024-11-19

基金资助

中国人民解放军后勤重大项目基金资助项目(AWS17J008)

Chronic cough: Current status and prospects

  • Lu LIU ,
  • Xiaoji ZHU ,
  • Yuxu. ZHONG
Expand
  • *.Department of Respiratory Medicine,Jiaozhou Branch of Shanghai East Hospital,Tongji University,Qingdao 266300,Shandong,China

Received date: 2024-03-10

  Online published: 2024-11-19

摘要

慢性咳嗽(chronic cough,CC)是常见的呼吸道症状,其发病率高达10% ~ 20%。慢性咳嗽的危害包括患者所经历的物理效应(如应激性尿失禁、睡眠障碍、胸痛)、心理后果(如失望、焦虑抑郁状态)以及社交障碍(如社交忧虑/孤立和生活质量下降)。因此,慢性咳嗽一直是困惑患者和临床医生的难题。该文结合国内外文献新理念,就慢性咳嗽概念、流行病学、发病机制、病因构成、临床表现及辅助检查、诊断与鉴别、治疗及展望等方面进行阐述。

本文引用格式

刘路 , 祝筱姬 , 钟玉绪 . 慢性咳嗽:现状与展望[J]. 实用医学杂志, 2024 , 40(21) : 3107 -3112 . DOI: 10.3969/j.issn.1006-5725.2024.21.023

Abstract

Chronic cough (CC) is a common respiratory disorders, with prevalence rates as high as 10% ~ 20%. The burden of CC can be severe, as patients with CC experience substantial physical effects (e.g., stress urinary incontinence, sleep disturbance, and chest pain), psychological consequences (e.g., frustration, anxiety, and depression), and social impairments (e.g., social distress/isolation and reduced quality of life). As a result, CC is a frustrating conundrum for patients and clinicians. In this paper, combined with the new concepts of domestic and foreign literature, we expound the concept of CC, epidemiology, pathogenesis, etiological structure, clinical manifestations and auxiliary examination, diagnosis and differential diagnosis, treatment, and future prospects, etc., for peer reference and learn from, so as to promote more in-depth related clinical research.

参考文献

1 DE VINCENTIS A, BALDI F, CALDERAZZO M, et al. Chronic cough in adults: recommendations from an Italian intersociety consensus[J]. Aging Clin Exp Res, 2022,34(7):1529-1550. doi:10.1007/s40520-022-02154-4
2 DICPINIGAITIS P V, LIM L, FARMAKIDIS C. Cough syncope[J]. Respir Med, 2014,108(2):244-251. doi:10.1016/j.rmed.2013.10.020
3 MORICE A H, MILLQVIST E, BELVISI M G, et al. Expert opinion on the cough hypersensitivity syndrome in respiratory medicine[J]. Eur Respir J, 2014,44(5):1132-1148. doi:10.1183/09031936.00218613
4 NEGRO R W DAL, MAZZOLINI M, TURCO P, et al. Cough: impact, beliefs, and expectations from a national survey[J]. Multidiscip Respir Med,2016,11:34. doi:10.1186/s40248-016-0072-1
5 ARINZE J T, DE ROOS E W, KARIMI L, et al. Prevalence and incidence of, and risk factors for chronic cough in the adult population: The rotterdam study[J]. ERJ Open Res, 2020,6(2):00300-2019. doi:10.1183/23120541.00300-2019
6 CHAMBERLAIN S A, GARROD R, DOUIRI A, et al. The impact of chronic cough: A cross-sectional European survey[J]. Lung, 2015,193(3):401-408. doi:10.1007/s00408-015-9701-2
7 CANNING B J, MORI N, MAZZONE S B. Vagal afferent nerves regulating the cough reflex[J]. Respir Physiol Neurobiol, 2006,152(3):223-242. doi:10.1016/j.resp.2006.03.001
8 GRONEBERG D A, NIIMI A, DINH Q T, et al. Increased expression of transient receptor potential vanilloid-1 in airway nerves of chronic cough[J]. Am J Respir Crit Care Med, 2004,170(12):1276-1280. doi:10.1164/rccm.200402-174oc
9 UNDEM B J, CHUAYCHOO B, LEE M G, et al. Subtypes of vagal afferent C-fibres in guinea-pig lungs[J]. J Physiol, 2004,556(3):905-917. doi:10.1113/jphysiol.2003.060079
10 陈颖, 黄俊文, 杨淑銮, 等. 咳嗽变异性哮喘与嗜酸粒细胞性支气管炎表型与疗程研究进展[J]. 实用医学杂志, 2022,38(15):1851-1855. doi:10.3969/j.issn.1006-5725.2022.15.001
11 YI F, JIANG Z, LI H, et al. Small airway dysfunction in cough variant asthma: prevalence, clinical, and pathophysiological features[J]. Front Physiol, 2022,12:761622. doi:10.3389/fphys.2021.761622
12 NIETO L, DE DIEGO A, PERPI?á M, et al. Cough reflex testing with inhaled capsaicin in the study of chronic cough[J]. Respir Med, 2003,97(4):393-400. doi:10.1053/rmed.2002.1460
13 TARLO S M. Lessons from occupational eosinophilic bronchitis[J]. J Allergy Clin Immunol Pract, 2021,9(2):945-946. doi:10.1016/j.jaip.2020.10.008
14 SIMON L M, JAQUA E E, NGUYEN V, et al. Respiratory symptom evaluation in adults: chronic cough[J]. FP Essent, 2023,528:7-11.
15 BRIGHTLING C E, BRADDING P, SYMON FA, et al. Mast-cell infiltration of airway smooth muscle in asthma[J]. Respir Med, 2007,101(5):1045. doi:10.1016/j.rmed.2007.01.004
16 SONG W J, WON H K, AN J, et al. Chronic cough in the elderly[J]. Pulm Pharmacol Ther, 2019,56:63-68. doi:10.1016/j.pupt.2019.03.010
17 NGUYEN M A, BACCI E D, VERNON M, et al. Validation of a visual analog scale for assessing cough severity in patients with chronic cough[J]. Ther Adv Respir Dis, 2021,15:17534666211049743. doi:10.1177/17534666211049743
18 MATHUR A, LIU-SHIU-CHEONG P S K, MUNRO A, et al. Chronic cough: A practical approach to assessment and management[J]. Drug Ther Bull, 2019,57(5):74-79. doi:10.1136/dtb.2018.000014
19 IRWIN R S, FRENCH C L, CHANG A B, et al. Classification of cough as a symptom in adults and management algorithms: CHEST guideline and expert panel report[J]. Chest, 2018,153(1):196-209.
20 BONVINI S J, BIRRELL M A, GRACE M S, et al. Transient receptor potential cation channel, subfamily V, member 4 and airway sensory afferent activation: role of adenosine triphosphate[J]. J Allergy Clin Immunol, 2016,138(1):249-261. doi:10.1016/j.jaci.2015.10.044
21 YANG J, CRAWLEY B, DEHOM S, et al. Chronic refractory cough: objective improvement with aerodynamic-focused[J]. J Voice, 2021,35(2):324.e9-324.e13. doi:10.1016/j.jvoice.2019.08.026
22 SMITH J A, BADRI H. Cough: new pharmacology[J]. J Allergy Clin Immunol Pract, 2019,7(6):1731-1738. doi:10.1016/j.jaip.2019.04.027
23 THOMAS D, GIBSON P G. Gefapixant for chronic cough[J]. Lancet, 2022, 399(10328):886-887. doi:10.1016/s0140-6736(21)02438-7
24 SHAPIRO C O, PROSKOCIL B J, OPPEGARD L J, et al. Airway sensory nerve density is increased in chronic cough[J]. Am J Respir Crit Care Med, 2020,203(3):348-355. doi:10.1164/rccm.201912-2347oc
25 MUCCINO D, GREEN S. Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough[J]. Pulm Pharmacol Ther, 2019,56:75-78. doi:10.1016/j.pupt.2019.03.006
26 MORICE A, SMITH J, MCGARVEY L, et al. Eliapixant (BAY 1817080), A P2X3 receptor antagonist, in refractorychronic cough: a randomised, placebo-controlled, crossover phase 2a study[J]. Eur Respir J, 2021,58(5): 2004240. doi:10.1183/13993003.04240-2020
27 GARCEAU D, CHAURET N. BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration[J]. Pulm Pharmacol Ther, 2019,56:56-62. doi:10.1016/j.pupt.2019.03.007
28 DICPINIGAITIS P V, MCGARVEY L P, CANNING B J. P2X3-receptor antagonists as potential antitussives: Summary of current clinical trials in chronic cough[J]. Lung, 2020,198(4): 609-616. doi:10.1007/s00408-020-00377-8
29 NGUYEN V, ZHANG Q, PAN F, et al. Zi-Su-Zi decoction improves airway hyperresponsiveness in cough-variant asthma rat model through PI3K/AKT1/mTOR, JAK2/STAT3 and HIF-1α/NF-κB signaling pathways[J]. J Ethnopharmacol, 2023,314:116637. doi:10.1016/j.jep.2023.116637
30 JIANG H, BAI Z, OU Y, et al. β-Hydroxybutyric acid upregulated by Suhuang antitussive capsule ameliorates cough variant asthma through GSK3β/AMPK-Nrf2 signal axis[J]. J Ethnopharmacol, 2023,307:116013. doi:10.1016/j.jep.2022.116013
文章导航

/